S. Phan

3.6k total citations · 2 hit papers
43 papers, 2.5k citations indexed

About

S. Phan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, S. Phan has authored 43 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in S. Phan's work include Cancer Treatment and Pharmacology (15 papers), Brain Metastases and Treatment (13 papers) and Lung Cancer Research Studies (10 papers). S. Phan is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Brain Metastases and Treatment (13 papers) and Lung Cancer Research Studies (10 papers). S. Phan collaborates with scholars based in United States, France and Canada. S. Phan's co-authors include Adam Brufsky, Véronique Dièras, Edith A. Perez, John A. Glaspy, Nicholas J. Robert, Igor Bondarenko, Oleg Lipatov, Joyce O’Shaughnessy, Stephen Chan and Xian Zhou and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

S. Phan

43 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

2011 766 citations Nicholas J. Robert, Véronique Dièras et al. Journal of Clinical Oncology profile →
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

2013 370 citations Jerome H. Goldschmidt, George R. Blumenschein et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Phan United States	15	1.6k	1.4k	547	525	495	43	2.5k
Susan C. Guba United States	22	1.3k 0.8×	784 0.6×	231 0.4×	350 0.7×	675 1.4×	49	2.4k
Holger Thurm United States	19	1.4k 0.9×	1.7k 1.2×	242 0.4×	470 0.9×	624 1.3×	48	2.2k
Cristian Massacesi Italy	20	1.6k 1.0×	1.1k 0.8×	245 0.4×	288 0.5×	984 2.0×	67	2.4k
Garry Schwartz United States	24	1.1k 0.6×	725 0.5×	336 0.6×	323 0.6×	760 1.5×	40	2.0k
Leslie B. Lee United States	13	790 0.5×	988 0.7×	284 0.5×	325 0.6×	1.0k 2.1×	13	2.3k
Tinya J. Abrams United States	12	835 0.5×	824 0.6×	211 0.4×	322 0.6×	936 1.9×	17	2.1k
D. J. Richel Netherlands	18	1.6k 1.0×	894 0.7×	236 0.4×	513 1.0×	725 1.5×	38	2.6k
Annetta Krebs United States	8	2.0k 1.2×	1.9k 1.4×	117 0.2×	395 0.8×	723 1.5×	8	2.8k
Radek Lakomý Czechia	22	1.3k 0.8×	806 0.6×	296 0.5×	1.0k 2.0×	1.2k 2.4×	87	2.8k
Giulio Metro Italy	33	2.2k 1.3×	1.8k 1.3×	302 0.6×	573 1.1×	1.0k 2.1×	169	3.3k

Countries citing papers authored by S. Phan

Since Specialization

Citations

This map shows the geographic impact of S. Phan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Phan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Phan more than expected).

Fields of papers citing papers by S. Phan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Phan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Phan. The network helps show where S. Phan may publish in the future.

Co-authorship network of co-authors of S. Phan

This figure shows the co-authorship network connecting the top 25 collaborators of S. Phan. A scholar is included among the top collaborators of S. Phan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Phan. S. Phan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

García‐Estévez, Laura, Aditya Bardia, Hope S. Rugo, et al.. (2025). The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. ESMO Open. 10(6). 105294–105294. 1 indexed citations

Xiao, Guang‐Qian, et al.. (2024). Clinicopathologic Study of 28 Cases of Tubulocystic Renal Cell Carcinoma: Is It Time to Reclassify It as a Tubulocystic Renal Cell Tumor? . Cureus. 16(11). e74015–e74015. 1 indexed citations

O’Shaughnessy, Joyce, Adam Brufsky, Hope S. Rugo, et al.. (2021). 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC). Annals of Oncology. 32. S473–S474. 2 indexed citations

NISHIO, MAKI, Fabrice Barlési, S. Ball, et al.. (2020). 375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC. Annals of Oncology. 31. S1386–S1387. 9 indexed citations

Rusch, Valerie W., Jamie E. Chaft, Bruce E. Johnson, et al.. (2018). MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3). Journal of Thoracic Oncology. 13(10). S369–S369. 9 indexed citations

Velcheti, Vamsidhar, Tarek Mekhail, Ticiana Leal, et al.. (2018). Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii744–viii744. 47 indexed citations

Lin, Steven H., Lin Xiao, Daniel L. Clay, et al.. (2018). OA01.06 DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S320–S321. 20 indexed citations

Mok, Tony, Shirish M. Gadgeel, Vamsidhar Velcheti, et al.. (2017). Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC. Annals of Oncology. 28. v494–v495. 12 indexed citations

Robert, Nicholas J., Véronique Dièras, John A. Glaspy, et al.. (2011). RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer. Journal of Clinical Oncology. 29(10). 1252–1260. 766 indexed citations breakdown →

10.

Bondarenko, Igor, John A. Glaspy, Adam Brufsky, et al.. (2010). 476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1. European Journal of Cancer Supplements. 8(3). 198–198. 1 indexed citations

11.

Carlson, Robert W., Richard L. Theriault, Edgardo Rivera, et al.. (2010). Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor–Positive, Metastatic Carcinoma of the Breast in Premenopausal Women. Journal of Clinical Oncology. 28(25). 3917–3921. 69 indexed citations

12.

William, William N., Ralph Zinner, Daniel D. Karp, et al.. (2007). Phase I Trial of Motexafin Gadolinium in Combination with Docetaxel and Cisplatin for the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(8). 745–750. 22 indexed citations

13.

Chung, Cathie T., et al.. (2007). Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer. Journal of Clinical Oncology. 25(18_suppl). 1030–1030. 9 indexed citations

14.

Mehta, Minesh P., R. Gervais, Pierre Chabot, et al.. (2006). Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial. Journal of Clinical Oncology. 24(18_suppl). 7014–7014. 20 indexed citations

15.

Phan, S., et al.. (2006). Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC). Journal of Clinical Oncology. 24(18_suppl). 14518–14518. 2 indexed citations

16.

Jac, J., et al.. (2005). Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC). Journal of Clinical Oncology. 23(16_suppl). 4724–4724. 1 indexed citations

17.

Shapiro, William R., Jennifer A. Smith, Roy A. Patchell, et al.. (2005). Validation of blinded events review committee (ERC)-determined time to neurologic progression (TTNP) demonstrates correlation with survival, radiologic progression, and functional independence endpoints. Journal of Clinical Oncology. 23(16_suppl). 1534–1534. 2 indexed citations

18.

Ramnath, Nithya, Gurkamal Chatta, Merrill J. Egorin, S. Phan, & Patrick J. Creaven. (2004). A phase 1 trial of motexafin gadolinium and docetaxel for advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3171–3171. 1 indexed citations

19.

Meyers, Christina A., Jennifer A. Smith, Andrea Bezjak, et al.. (2003). Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 22(1). 157–165. 423 indexed citations

20.

Mehta, Minesh P., Patrick Rodrigus, Chris H.J. Terhaard, et al.. (2001). Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium. International Journal of Radiation Oncology*Biology*Physics. 51(3). 135–136. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact